Clinical trials: GERD - PPI Responders
Gastroesophageal Reflux Disease (GERD)
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI…
- Trial name
- REMAIN (NCT00795093)
- Where
- 53 sites in United States
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump…
- Trial name
- NCT00978016
- Testing
- arbaclofen placarbil-Cohort 1, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3
- Where
- 64 sites in United States, Canada
- Volunteers
- 460 people
- Sponsor
- XenoPort, Inc.
Gastroesophageal Reflux
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
- Trial name
- NCT05556824
- Testing
- MHS-1031
- Where
- 18 sites in United States
- Volunteers
- 255 people
- Sponsor
- Microbiome Health Sciences
Gastroesophageal Reflux Disease
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with…
- Trial name
- NCT00730665
- Testing
- PF-00885706, Esomeprazole
- Where
- 38 sites in Belgium, Brazil and 5 more
- Volunteers
- 81 people
- Sponsor
- Pfizer
Gastroesophageal Reflux Disease
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI…
- Trial name
- REMAIN (NCT00842855)
- Where
- 44 sites in France
- Volunteers
- 275 people
- Sponsor
- AstraZeneca